Chinese low cost immunotherapy drugs are easing cancer bills for Indian families

Lower cost access is changing outcomes and debts for families

India’s cancer care is shifting as cheaper immunotherapy drugs developed in China arrive through Indian partnerships. Oncologists say these options are expanding access for patients who cannot afford pricier Western medicines. The result, doctors claim, is less financial strain and fewer cases where cancer treatment drives families into severe debt, alongside improving affordability of sustained care.